An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) ...

Cardiff Oncology’s investigational PLK1 inhibitor paired with standard-of-care treatment showed a 64% overall response rate ...

Radiation is one of the most effective ways to kill a tumor. But these therapies are indiscriminate, and they can damage ...

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS ...

Human cell transformation systems revealed that RAL-GEF signaling is particularly required for oncogenic RAS function in human cancer. Murine Kras-driven lung cancer models have confirmed the key ...

Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264 ...

Imagine a cancer treatment so precise it could destroy tumors while leaving healthy tissue untouched. Researchers at the ...

A UT Southwestern trial found selinexor, an FDA-approved drug, effective in KRAS-mutated non-small cell lung cancer (NSCLC).

Memorial Sloan Kettering Cancer Center: “Lung Cancer Genomic Testing (EGFR, KRAS, ALK).” National Cancer Institute: “Understanding laboratory tests.” Late-Stage NSCLC: What your doctor may ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

This page includes links to articles highlighting the top lung cancer research published on Cancer Therapy Advisor in 2024.

BAY3498264 is an investigational oral selective SOS1 inhibitor with potential to treat a variety of KRAS-mutated cancers, such as non-small cell lung cancer, pancreatic cancer and colorectal cancer ...